Press Releases
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
OCALA, Fla., Oct. 03, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both compositions and methods comprising the...
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
OCALA, Fla., Sept. 30, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of common stock in a registered...
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ETOCALA, Fla., Sept. 27, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, Chief...
Stock Information
Recent SEC Filings
Corporate Presentation